Navigation Links
XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
Date:10/16/2007

Company Also to Host Drug-Eluting Stent Symposium and Analyst Webcast

MENLO PARK, Calif., Oct. 16 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX(R) drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.

In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.

Schedule of Events

Sunday, October 21

Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting

Modular Stent Program (Focus on Multivessel and Diffuse Disease)

Pieter Stella, M.D., Director of Cardiology, University Medical Center,

Utrecht, Netherlands, will present a historical overview and current

perspective on the treatment of multivessel coronary disease and the

treatment of long lesions. An overview of the Custom NX(R) DES System with

respect to the treatment of multivessel and diffuse disease will be

discussed, along with the one-year follow-up results of the CUSTOM II

Trial.

Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington

Convention Center

Event: Evening Symposium -- Delivering Safety to Today's Patients

Professor Eberhard Grube, M.D., Chief
'/>"/>

SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 PharmaEngine, Inc. (TWO:4162) today announced ... MACK ) with its sublicensing partner, Baxter ... that Baxter has submitted a marketing authorization application ... MM-398 (irinotecan liposome injection), also known as "nal-IRI," ... who have been previously treated with gemcitabine-based therapy. ...
(Date:5/4/2015)... 2015  Oncobiologics, Inc., a biotherapeutics company focused ... has completed the construction of its GMP commercial ... Cranbury, New Jersey . ... designed to utilize multiple technologies that enable rapid ... the use of the latest single-use technologies, the ...
(Date:5/4/2015)... , May 4, 2015   HeartWare International, Inc ... invasive, miniaturized circulatory support technologies that are revolutionizing the treatment ... Doug Godshall , is scheduled to present at the ... Las Vegas on Thursday, May 14, ... The live webcast of the Company,s presentation at the conference ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... I clinical trial in healthy subjects- Study aims ... new vaccine candidate- Initial results expected in Q4 ... by PATHVIENNA, April 7 Intercell AG (VSE: ... trial with the company,s vaccine candidate IC47 to ...
... Glycotex, Inc. today announced the completion of a scheduled ... effect of investigational GLYC-101 gel on complete wound closure ... dioxide laser skin resurfacing on the lower eyelid area.The ... study. The comparison of each active arm to placebo ...
Cached Medicine Technology:Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine 2Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine 3Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis 2Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis 3
(Date:5/4/2015)... LiveSchool ” was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... students with good behavior. , Positive re-enforcement is more ... And the good people at LiveSchool have taken note ...
(Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 In May ... Smalley took his own life. In the wake of this ... the Silent, an organization that exposes the grim reality of ... also a platform for Kirk and Laura to share their ... their tragedy from happening to another family — a mission ...
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
(Date:5/4/2015)... May 04, 2015 EyeCRO LLC and ... to facilitate development of NM108, a first-in-class small molecule ... to blindness, including Diabetic Retinopathy. The collaboration grants ... by EyeCRO, which can deliver drugs to the front ... , Under the terms of the agreement, EyeCRO ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3
... ROCKFORD, Mich., Aug. 31 Pediatric Wildlife Care Tables, ... answer to an age-old problem for doctors, nurses and healthcare ... , , Constantly in need of ... long relied on bulky rolling computer tables to temporarily stow ...
... along with alcohol use, survey shows , MONDAY, Aug. ... are often exercisers. , According to a new University ... the American Journal of Health Promotion , the ... exercise. , "Alcohol users not only exercised more ...
... , Politics and Possibilities of Health ... WASHINGTON, Aug. 31 URAC ... that several key policy makers and insurance leaders will lead a discussion, ... Care Landscape," at URAC,s 10th Annual Quality Summit and Exhibit ...
... , , , ... (Nasdaq: PPHM ), today announced that noted cancer researcher Bruce ... the design of clinical trials for the bavituximab cancer program. Dr. ... Center, chief of hematology and oncology at MGH and a professor of ...
... 31 /PRNewswire-Asia/ -- Sundia MediTech Company, a leading,pharmaceutical ... that,it received the Highest Growth Potential Award from ... announced at the 10th anniversary celebration of,"Focus on ... Vice President,for Process Chemistry and GMP Operations, attended ...
... , , , ... medical technology systems integrator transforming critical care, announced that former Veterans ... Board of Advisors. , , Secretary Peake retired ... and commander in several medical posts culminating in his appointment as ...
Cached Medicine News:Health News:Foldaway Pediatric Point of Care Table Provides Efficient Work Surface Without Compromising Space 2Health News:Drinkers May Exercise More Than Teetotalers 2Health News:Policy Makers Discuss Health Care Reform at URAC Quality Summit 2Health News:Policy Makers Discuss Health Care Reform at URAC Quality Summit 3Health News:Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs 2Health News:Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs 3Health News:Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs 4Health News:Sundia Receives the Highest Growth Potential Award from Zhangjiang 2Health News:Former Veterans Affairs Secretary Joins Integrated Medical Systems' Advisory Board 2Health News:Former Veterans Affairs Secretary Joins Integrated Medical Systems' Advisory Board 3
... Wampole Laboratories offers a comprehensive line ... for serum and urine in convenient one-step ... offers 2 testing options. Clearview Easy HCG ... a convenient stick format. Clearview HCG ...
... line of pregnancy tests including rapid membrane ... one-step stick and cassette formats. The Clearview ... HCG is a 25 mIU urine test ... HCG II provides 25mIU sensitivity for urine ...
For the quantitative determination of Glycohemoglobin (HbA1) in blood by,cation exchange resin. The test is to be used to monitor long-term glucose,control in diabetes mellitus....
Rapid turn-around time, results in less than 4 hours...
Medicine Products: